April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Comparison Of Anti-mt1-mmp And Anti-vegf Therapy In Age-related Macular Degeneration (amd) Choroidal Neovascularization (cnv) Model
Author Affiliations & Notes
  • George Inana
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Claudius Tapia
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Yoshihiro Mizutani
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Christopher Murat
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Margaret McLaren
    iTherapeutics, Miami, Florida
  • Footnotes
    Commercial Relationships  George Inana, 7309487 (P), iTherapeutics (F, I); Claudius Tapia, None; Yoshihiro Mizutani, None; Christopher Murat, None; Margaret McLaren, 7309487 (P), iTherapeutics (I, E)
  • Footnotes
    Support  iTherapeutics, Inc., NIH P30 EY014801, an unrestricted grant to the University of Miami from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 947. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      George Inana, Claudius Tapia, Yoshihiro Mizutani, Christopher Murat, Margaret McLaren; Comparison Of Anti-mt1-mmp And Anti-vegf Therapy In Age-related Macular Degeneration (amd) Choroidal Neovascularization (cnv) Model. Invest. Ophthalmol. Vis. Sci. 2011;52(14):947.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : We have identified membrane-type matrix metalloproteinase 1 (MT1-MMP) as a candidate gene for AMD by a custom expression profiling strategy called CHANGE based on its 1) over-expression in human AMD eyes, and 2) role in photoreceptor outer segment (OS) phagocytosis by the RPE, a key function and daily burden for the RPE cells which are primarily affected in AMD. We have constructed a proof-of-concept transgenic mouse (Tg) model that conditionally over-expresses MT1-MMP and produces a phenotype similar to that found in both the dry and wet form of AMD, supporting the involvement of this gene in the pathogenesis of AMD. In this study we analyzed the efficacy of antibodies to MT1-MMP and VEGF in suppressing the formation of CNV in the mouse laser photocoagulation model.

Methods: : Activity-neutralizing antibodies to MT1-MMP or VEGF were intravitreally injected into mouse eyes, and CNV was induced by laser photocoagulation. After 2 weeks, the extent of CNV was analyzed in ocular flatmounts from the mice, taking into consideration both the fluorescence and the size of the lesions (CNV index).

Results: : The results of 14 experiments assessing the efficacy of anti-MT1-MMP antibody showed a significant ameliorative effect on CNV formation over the control eye. With untreated control lesions being normalized to a CNV index value of 1.0, the MT1-MMP treatment resulted in a CNV index of 0.52 (p=0.0000015). In 6 of these experiments in which anti-VEGF antibody was compared to anti-MT1-MMP antibody, the effect of anti-VEGF Ab showed no difference from control (CNV index ratio of 1.60 (p=0.07) for anti-VEGF Ab). The difference between the two treatments was statistically significant by the paired test (p=0.016).

Conclusions: : Anti-MT1-MMP treatment was shown to be effective against CNV formation in the mouse AMD model, confirming the importance of this gene/protein in the pathogenesis of AMD. The efficacy of CNV suppression by anti-MT1-MMP antibody was superior to that of anti-VEGF antibody in the mouse model. Studies are planned to extend these results in non-human primates.

Keywords: age-related macular degeneration • choroid: neovascularization • candidate gene analysis 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.